SURVIVAL OF NONCURATIVELY RESECTED LUNG-CANCER

被引:15
|
作者
KIMURA, H [1 ]
YAMAGUCHI, Y [1 ]
机构
[1] CHIBA UNIV, SCH MED, INT PULM CANC RES, DEPT SURG, CHUO KU, CHIBA 260, JAPAN
关键词
LUNG CANCER; CURATIVITY; SURGERY; NONCURATIVE RESECTION; ADJUVANT THERAPY;
D O I
10.1016/0169-5002(94)90543-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Out of 858 patients who underwent thoracotomy for primary lung cancer, 279 cases were classified as non-curative on the basis of intraoperative and/or post-operative examinations. The causes for non-curative resection were defined as follows: (I) absolutely non-curative resection, (1) palliative tumor extirpation (palliative), (2) remaining tumor in (a) lymph nodes (Ly rem), (b) chest wall or diaphragm (Ch/Dia rem), or (c) bronchial stump (Pro rem), (3) intrapulmonary metastasis (PM), (4) pleural dissemination or pleuritis carcinomatosa (Pl/Diss), (5) metastasis in other organs (Meta); (II) relatively non-curative resection, (1) incomplete resection of lymph nodes (RO-1), (2) group 2b or 3 lymph node metastasis (2b Ly). The 5-year actuarial survival rate of the Pro rem group was 35.6%, being the best among the absolutely non-curative cases, followed by the PM group (33.7%), the Pl/Diss group (31.6%) and the Ch/Dia rem group (29.7%). The results of the Ly rem and Meta groups were poor at 5.4% and 0%, respectively. Those of the relatively non-curative group were 24.4% (RO-1 group) and 11.6% (2b Ly group). Non-curative resection is not the treatment of choice, but by analyzing the causes of non-curative resection, we may able to improve the prognosis of advanced cases of lung cancer.
引用
收藏
页码:229 / 242
页数:14
相关论文
共 50 条
  • [41] PREDICTORS OF SURVIVAL IN PATIENTS WITH PRIMARY LUNG-CANCER
    MILLER, S
    RODER, D
    ANTIC, R
    MCLENNAN, G
    MEDICAL AND PEDIATRIC ONCOLOGY, 1987, 15 (03): : 134 - 134
  • [42] LEUCOCYTE-COUNTS AND SURVIVAL IN LUNG-CANCER
    HUHTI, E
    POUKKULA, A
    SALOHEIMO, M
    LANCET, 1979, 1 (8130): : 1348 - 1348
  • [43] NEW SURVIVAL STANDARDS FOR INOPERABLE LUNG-CANCER
    LANZOTTI, VJ
    THOMAS, DR
    SMITH, TL
    HOWE, CD
    SAMUELS, ML
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1976, 17 (MAR): : 99 - 99
  • [44] LUNG-CANCER INCIDENCE AND SURVIVAL BY HISTOLOGIC TYPE
    TRAVIS, WD
    TRAVIS, LB
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1993, 147 (04): : A775 - A775
  • [45] BRAIN METASTASES IN RESECTED NON-OAT CELL LUNG-CANCER
    MARTINI, N
    POSNER, J
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 421 - 421
  • [46] REASSESSMENT OF THE ROLE OF POSTOPERATIVE RADIATION-THERAPY IN RESECTED LUNG-CANCER
    CHOI, NC
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1982, 8 (11): : 2015 - 2018
  • [47] PROGNOSTIC ASSESSMENT OF RESECTED NEUROENDOCRINE LUNG-CANCER AT EARLY-STAGE
    LEQUAGLIE, C
    CATALDO, J
    PREDA, F
    RAVASI, G
    AMERICAN REVIEW OF RESPIRATORY DISEASE, 1993, 147 (04): : A746 - A746
  • [48] ADJUVANT IMMUNOTHERAPY OF PRIMARY RESECTED LUNG-CANCER WITH TRANSFER-FACTOR
    FUJISAWA, T
    YAMAGUCHI, Y
    KIMURA, H
    ARITA, M
    BABA, M
    SHIBA, M
    CANCER, 1984, 54 (04) : 663 - 669
  • [49] EXPRESSION OF DIFFERENT CYTOSKELETAL PEPTIDES IN RESECTED NONSMALL CELL LUNG-CANCER
    PENDLETON, N
    MYSKOW, MW
    GREEN, JA
    THORAX, 1992, 47 (03) : P249 - P250
  • [50] POSTOPERATIVE CHEMOTHERAPY FOR RESECTED NON-SMALL-CELL LUNG-CANCER
    CRUMP, M
    WORLD JOURNAL OF SURGERY, 1993, 17 (06) : 735 - 740